Trial · NCT01860586
Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.
NCT01860586, Not applicable, Completed, Wills Eye; results first posted 2017-04-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment. Trials, record NCT01860586. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01860586
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.
- NCT number
- NCT01860586
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- Wills Eye
- Conditions
- Retinal Detachment, Vitreoretinopathy Proliferative
- Interventions
- Bevacizumab
- First posted
- 2013-05-22
- Last updated
- 2017-04-17
- Results first posted
- 2017-04-17
- Limitations and caveats
- This pilot study has several limitations, including small sample size, its non-randomized nature, and use of historical controls for outcome comparisons.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) | up to 6 months | This will be assessed by the frequency (occurences) of retinal detachments in patients that have intravitreal bevacizumab injections versus prior patients that did not have intravitreal bevacizumab injections. |
| Secondary | The Effect of Intravitreal Bevacizumab Injections on the Development of Epiretinal Membranes (Increase or Decrease) | 6 months | To determine if intravitreal bevacizumab injections will increase or decrease the occurences (cases) of epiretinal membranes . |
| Other | Intravitreal Bevacizumab Injections Impact on Visual Acuity Score (Change in Letters Read). | 6 months | Increase or decrease in amount of letters read after intravitreal bevacizumab injections versus control patient that did not receive injections of intravitreal bevacizumab. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) | up to 6 months | Bevacizumab treated patients with recurrent retinal detachment | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | The Effect of Intravitreal Bevacizumab Injections on the Development of Epiretinal Membranes (Increase or Decrease) | 6 months | Number of patients treated with bevacizumab who developed epiretinal membrane | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Intravitreal Bevacizumab Injections Impact on Visual Acuity Score (Change in Letters Read). | 6 months | Final logMAR visual acuity of patients treated with bevacizumab | logMAR visual acuity | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) | Bevacizumab | 6 | Participants | ||
| The Effect of Intravitreal Bevacizumab Injections on the Development of Epiretinal Membranes (Increase or Decrease) | Bevacizumab | 7 | Participants | ||
| Intravitreal Bevacizumab Injections Impact on Visual Acuity Score (Change in Letters Read). | Bevacizumab | 1.43 | Standard Deviation 0.70 | logMAR visual acuity |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bevacizumab | 20 | |
| Overall Study | COMPLETED | Bevacizumab | 20 | |
| Overall Study | NOT COMPLETED | Bevacizumab | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bevacizumab | 0 | 20 |
| Total, other adverse events | Bevacizumab | 0 | 20 |
| Total, serious adverse events | Bevacizumab | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01860586
GET https://conductscience.org/api/trials/v1/NCT01860586/registered